Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2024-205230

Published: 2024

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Mathias J Rummel, MD PhD, Christian Lerchenmüller, MD, Manfred Hensel, MD, Martin Goerner, MD, Christian Buske, MD PhD, Holger Schulz, Burkhard Schmidt, MD, Georgi Kojouharoff, MD, Elisabeth Lange, MD, Wolfgang Willenbacher, MD PhD, Jan Dürig, Erik Engel, Frank Kauff, Jürgen Barth, Alexander Christoph Burchardt, MD, Axel Hinke, PhD, Jasmin Wupperfeld, Richard Greil, MD

Blood (2019) 134 (Supplement_1): 343.

https://doi.org/10.1182/blood-2019-121909

Published: 2019

Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Blood (2018) 132 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2018-99-113257

Published: 2018

Journal Articles

Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)

Blood (2017) 130 (Supplement 1): 494.

https://doi.org/10.1182/blood.V130.Suppl_1.494.494

Published: 2017

Journal Articles

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Leopold Sellner, MD, Oles Malgorzata, Mikolaj Slabicki, PhD, Carolin Blume, Hüllein Jennifer, Tatjana Stolz, Martin Sill, PhD, Sascha Dietrich, MD, Olaf Merkel, PhD, Anna Jauch, PhD, Manfred Hensel, MD, Davide Rossi, Zirlik Katja, MD, Martina Seiffert, PhD, Anthony D. Ho, MD, von Kalle Christof, MD, Hanno Glimm, MD, Wolfgang Huber, PhD, Thorsten Zenz, MD

Blood (2013) 122 (21): 173.

https://doi.org/10.1182/blood.V122.21.173.173

Published: 2013

Journal Articles

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

Mathias J. Rummel, MD, Christian Lerchenmüller, MD, Richard Greil, MD, Martin Görner, Manfred Hensel, MD, Erik Engel, Ulrich Jaeger, MD, Friedhelm Breuer, Bernd Hertenstein, Otto Prummer, MD, PhD, Christian Buske, MD, Juergen Barth, Alexander C. Burchardt, MD, Wolfram Brugger

Blood (2012) 120 (21): 2739.

https://doi.org/10.1182/blood.V120.21.2739.2739

Published: 2012

Journal Articles

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Blood (2012) 119 (21): 4851–4859.

https://doi.org/10.1182/blood-2011-09-378505

Published: 2012

Includes: Supplemental data

Journal Articles

Excellent Long-Term Survival of Patients with Waldenström‘s Macroglobulinemia (WM) treated in Private Oncology Practices and a University hospital with different Treatment Strategies

Manfred Hensel, MD, Jürgen Brust, MD, PhD, Christoph Plöger, MD, Dieter Schuster, MD, Marie-Luise Memmer, Michael Rieger, MD, Lara Hensel, Solveigh Mosthaf, Judith Franz-Werner, MD, Hans-Peter Feustel, MD, Franz Mosthaf, MD, Andreas Karcher, MD, Stefan Fuxius, MD, Anthony D. Ho, MD, Mathias Witzens-Harig, MD

Blood (2011) 118 (21): 2671.

https://doi.org/10.1182/blood.V118.21.2671.2671

Published: 2011

Journal Articles

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Mathias Witzens-Harig, MD, Axel Benner, Michael Rieger, MD, Fabienne McClanahan, MD, Manfred Hensel, MD, Kai Neben, MD, Peter Dreger, MD, Eva Lengfelder, MD, Ingo Schmidt-Wolf, MD, Alwin Krämer, MD, PhD, Anthony D. Ho, MD

Blood (2011) 118 (21): 3700.

https://doi.org/10.1182/blood.V118.21.3700.3700

Published: 2011

Journal Articles

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.

Mathias Witzens-Harig, Axel Benner, Michael Rieger, Fabienne McClanahan, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt-Wolf, Krämer Alwin, Anthony D. Ho

Blood (2009) 114 (22): 1707.

https://doi.org/10.1182/blood.V114.22.1707.1707

Published: 2009

Journal Articles

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Martin Bentz, MD, Ingo Schmidt-Wolf, Andreas Kaebisch, MD, Hans-Jürgen Salwender, Heinz Dürk, Hans Juergen Staiger, MD, Thomas Mandel, MD, Kai Neben, MD, Jens Hillengass, MD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2687.

https://doi.org/10.1182/blood.V114.22.2687.2687

Published: 2009

Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Blood (2009) 114 (22): 535.

https://doi.org/10.1182/blood.V114.22.535.535

Published: 2009

Journal Articles

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Peter Dreger, Hartmut Döhner, Hildegard Greinix, MD, Fabienne McClanahan, MD, Manfred Hensel, Bernd Hertenstein, Ulrich Dührsen, MD, PhD, Markus Hentrich, Lorenz Trümper, Ruth Sonnen, Bertold Emmerich, Wolfgang Ulrich Knauf, Georg Hopfinger, MD, Michael Hallek, Michael Kneba, MD, PhD, Norbert Schmitz, Stephan Stilgenbauer, MD

Blood (2009) 114 (22): 879.

https://doi.org/10.1182/blood.V114.22.879.879

Published: 2009

Journal Articles

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

Fabienne McClanahan, MD, Thomas Hielscher, Michael Rieger, MD, Manfred Hensel, MD, PhD, Kai Neben, Jens Hillengass, MD, Klaus Herfarth, MD, PhD, Anthony D. Ho, MD, PhD, Mathias Witzens-Harig, MD

Blood (2009) 114 (22): 2722.

https://doi.org/10.1182/blood.V114.22.2722.2722

Published: 2009

Journal Articles

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 329.

https://doi.org/10.1182/blood.V112.11.329.329

Published: 2008

Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Blood (2008) 112 (11): 325.

https://doi.org/10.1182/blood.V112.11.325.325

Published: 2008

Journal Articles

Quantitative Gene Expression Analysis of Surrogate Markers for Genetic Risk Groups and Survival in CLL

Dirk Kienle, Axel Benner, Dirk Winkler, Manfred Hensel, M.D., Riccardo Dalla-Favera, Peter Lichter, Stephan Stilgenbauer, MD, PhD, Hartmut Döhner

Blood (2008) 112 (11): 4170.

https://doi.org/10.1182/blood.V112.11.4170.4170

Published: 2008

NARROW

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Bendamustin-Rituximab Induction Followed by Observation or Rituximab Maintenance for Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Results From a Prospective, Randomized, Multicenter Study (StiL NHL 7–2008 –MAINTAIN-; ClinicalTrials.gov Identifier: NCT00877214).

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Excellent Long-Term Survival of Patients with Waldenström‘s Macroglobulinemia (WM) treated in Private Oncology Practices and a University hospital with different Treatment Strategies

Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,

Rituximab Maintenenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – Final Results of a Multicenter Prospective Randomised Phase II Study.

How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Combined with 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Lymphoma (HD2000-Trial).

Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.

Clinical Outcome of Patients with Follicular Lymphoma and Bulky Disease After Rituximab-CHOP Immunochemotherapy with and without Consolidating Radiotherapy.

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Quantitative Gene Expression Analysis of Surrogate Markers for Genetic Risk Groups and Survival in CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only